Evidence map›Paper›PMID 40268746›Full record

ArticleRheumatology (Oxford, England)2025

Real-world care patterns and specialist encounters of patients with systemic autoimmune rheumatic disease-related interstitial lung disease in the United States: a retrospective administrative claims database analysis.

Joseph Yang, Michael A Head, Kevin D Schott, Hiangkiat Tan, Rachel Djaraher, Christopher L Crowe, Mark Napier, Kenneth Kossack, Amy L Olson, Elana J Bernstein

Erratum issuedAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Joseph YangBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.ORCID 0009-0001-1874-8880
Michael A HeadHEOR, Carelon Research, Wilmington, DE, USA.ORCID 0000-0002-7815-6385
Kevin D SchottHEOR, Carelon Research, Wilmington, DE, USA.ORCID 0000-0003-3376-1634
Hiangkiat TanHEOR, Carelon Research, Wilmington, DE, USA.ORCID 0000-0002-1960-1493
Rachel DjaraherHEOR, Carelon Research, Wilmington, DE, USA.
Christopher L CroweHEOR, Carelon Research, Wilmington, DE, USA.
Mark NapierHealth and Wellness, Elevance Health, Inc, Latham, NY, USA.
Kenneth KossackBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Amy L OlsonBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Elana J BernsteinDivision of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-5560-6390

Funding

Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung DiseaseR01HL164758 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Elana J. Bernstein · 2022 to 2026
$3.5M
Screening Chest CT to Detect Interstitial Lung Disease in Systemic SclerosisK23AR075112 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERNSTEIN, ELANA · 2019 to 2023
$794k
Boehringer Ingelheim PharmaceuticalsNHLBI NIH HHS R01 HL164758NIAMS NIH HHS K23 AR075112
6 · The paper itself

Abstract

objectivesWe aimed to describe the demographics, clinical characteristics and care patterns of patients with systemic autoimmune rheumatic diseases (SARD) prior to their interstitial lung disease (ILD) diagnosis.

methodsWe conducted a retrospective cohort study using claims data from Healthcare Integrated Research Database (2006-2023). Adults diagnosed with SARD-ILD were identified, with the earliest ILD diagnosis date designated as the index date. A minimum of 36 months of continuous enrolment before the index date was required. All measures were analysed descriptively. For a subset of patients with respiratory symptoms before ILD diagnosis, the association between type of specialist encounter and time from symptom onset to SARD-ILD diagnosis was assessed using a Cox proportional hazards model.

resultsThe study included 2526 patients with SARD-ILD. Mean age was 62.6 years and 75.4% were female. Before ILD diagnosis, 61.8% of patients had at least one all-cause hospitalization. Diagnostic tests including chest CT, high-resolution CT, and pulmonary function tests (PFT) were used in 80.1%, 59.0% and 60.3% of patients, respectively. Among the subgroup, patients who saw a pulmonologist within 90 days of initial respiratory symptom onset were 18% more likely to be diagnosed with ILD compared with those who did not (hazard ratio: 1.18, 95% CI: 1.03, 1.35; P = 0.017).

conclusionThe study highlights the complex diagnostic journey of patients with SARD-ILD. Findings suggest a multidisciplinary approach involving pulmonologists and rheumatologists could enable timely ILD diagnosis and should be considered for more effective diagnosis and management of SARD-ILD.

Indexed as

Autoimmune DiseasesLung Diseases, InterstitialRheumatic DiseasesAdultAgedDatabases, FactualFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesUnited Statescare patternsdiagnosisinterstitial lung diseasesystemic autoimmune rheumatic diseases

Identifiers

PMID40268746
PMCPMC12316361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.